Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a study of BCMA-directed CAR-T cell therapy in progressive multiple sclerosis
MOH_2026-06-15_016878Phase 2Not yet recruiting
- Sponsor
- פרופ גל מרקל
- Start
- May 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RMC BCMA CAR T-cell therapy in multiple sclerosis (MS), sponsored by פרופ גל מרקל. Primary endpoints: Safety and tolerability and Change in EDSS. Planned start May 2026; status: not yet recruiting.
02
Drugs
RMC BCMA CAR T-cell therapy
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on MOH_2026-06-15_016878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-06-15_016878.